MYSTIC: Developing biomarkers for metastatic NSCLC

Bookmark and Share
Published: 11 Apr 2019
Views: 1966
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Prof Solange Peters speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the MYSTIC trial that aims to evaluate the opportunity of administering front-line immunotherapy in patients with metastatic NSCLC.

This three-arm randomised trial consisted of administering durvalumab, with or without tremelimumab versus platinum-based chemotherapy.

Prof Peters discusses why the primary endpoint did not reach statistical significance, despite achieving a clinically meaningful result that supported the use of durvalumab compared to chemotherapy.

Prof Peters also explains the role of the 'tumour mutational burden' as a clinical biomarker for this disease type in the future.